ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Revision as of 19:44, 12 February 2009 by Brian Blank (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Myocardial infarction
Diagram of a myocardial infarction (2) of the tip of the anterior wall of the heart (an apical infarct) after occlusion (1) of a branch of the left coronary artery (LCA, right coronary artery = RCA).
ICD-10 I21-I22
ICD-9 410
DiseasesDB 8664
MedlinePlus 000195
eMedicine med/1567  emerg/327 ped/2520

WikiDoc Resources for ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Articles

Most recent articles on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Most cited articles on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Review articles on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Articles on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Images of ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Photos of ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Podcasts & MP3s on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Videos on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Evidence Based Medicine

Cochrane Collaboration on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Bandolier on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

TRIP on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Clinical Trials

Ongoing Trials on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge at Clinical Trials.gov

Trial results on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Clinical Trials on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

NICE Guidance on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

NHS PRODIGY Guidance

FDA on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

CDC on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Books

Books on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

News

ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge in the news

Be alerted to news on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

News trends on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Commentary

Blogs on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Definitions

Definitions of ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Patient Resources / Community

Patient resources on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Discussion groups on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Patient Handouts on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Directions to Hospitals Treating ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Risk calculators and risk factors for ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Healthcare Provider Resources

Symptoms of ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Causes & Risk Factors for ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Diagnostic studies for ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Treatment of ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Continuing Medical Education (CME)

CME Programs on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

International

ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge en Espanol

ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge en Francais

Business

ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge in the Marketplace

Patents on ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Experimental / Informatics

List of terms related to ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge

Cardiology Network

Discuss ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Inhibition of the renin-angiotensin-aldosterone system is a key therapeutic maneuver in patients with STEMI.

Mechanism of Benefit [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]

Clinical Trial Data [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31]

Dosing

Side Effects

Guidelines

Guidelines for ACE Inhibitors Therapy [32]

Guidelines for Angiotensin Receptor Blockers Therapy [32]

Guidelines for Aldosterone Blockers Therapy [32]

Guidelines for Inhibition of the Renin-Angiotensin-Aldosterone System [32]

References

  1. "Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators". Lancet. 342 (8875): 821–8. 1993. PMID 8104270. Unknown parameter |month= ignored (help)
  2. Køber L, Torp-Pedersen C, Carlsen JE; et al. (1995). "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group". N. Engl. J. Med. 333 (25): 1670–6. PMID 7477219. Unknown parameter |month= ignored (help)
  3. "ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group". Lancet. 345 (8951): 669–85. 1995. PMID 7661937. Unknown parameter |month= ignored (help)
  4. "GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico". Lancet. 343 (8906): 1115–22. 1994. PMID 7910229. Unknown parameter |month= ignored (help)
  5. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H (1992). "Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)". N. Engl. J. Med. 327 (10): 678–84. PMID 1495520. Unknown parameter |month= ignored (help)
  6. Pfeffer MA (1998). "ACE inhibitors in acute myocardial infarction: patient selection and timing". Circulation. 97 (22): 2192–4. PMID 9631866. Unknown parameter |month= ignored (help)
  7. Rutherford JD, Pfeffer MA, Moyé LA; et al. (1994). "Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators". Circulation. 90 (4): 1731–8. PMID 7923656. Unknown parameter |month= ignored (help)
  8. Pfeffer MA, McMurray JJ, Velazquez EJ; et al. (2003). "Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both". N. Engl. J. Med. 349 (20): 1893–906. doi:10.1056/NEJMoa032292. PMID 14610160. Unknown parameter |month= ignored (help)
  9. Pitt B, Remme W, Zannad F; et al. (2003). "Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction". N. Engl. J. Med. 348 (14): 1309–21. doi:10.1056/NEJMoa030207. PMID 12668699. Unknown parameter |month= ignored (help)
  10. Pfeffer MA, Greaves SC, Arnold JM; et al. (1997). "Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial". Circulation. 95 (12): 2643–51. PMID 9193433. Unknown parameter |month= ignored (help)
  11. Tokmakova M, Solomon SD (2006). "Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials". Curr. Opin. Cardiol. 21 (4): 268–72. doi:10.1097/01.hco.0000231394.79609.24. PMID 16755193. Unknown parameter |month= ignored (help)
  12. Pitt B (2003). "Aldosterone blockade in patients with systolic left ventricular dysfunction". Circulation. 108 (15): 1790–4. doi:10.1161/01.CIR.0000086776.15268.22. PMID 14557343. Unknown parameter |month= ignored (help)
  13. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G (1995). "ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials". Circulation. 92 (10): 3132–7. PMID 7586285. Unknown parameter |month= ignored (help)
  14. Ambrosioni E, Borghi C, Magnani B (1995). "The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators". N. Engl. J. Med. 332 (2): 80–5. PMID 7990904. Unknown parameter |month= ignored (help)
  15. "Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group". Circulation. 97 (22): 2202–12. 1998. PMID 9631869. Unknown parameter |month= ignored (help)
  16. Teo KK, Yusuf S, Pfeffer M; et al. (2002). "Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review". Lancet. 360 (9339): 1037–43. PMID 12383982. Unknown parameter |month= ignored (help)
  17. Meune C, Mahe I, Mourad JJ; et al. (2000). "Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review". Eur. J. Clin. Pharmacol. 56 (9–10): 609–20. PMID 11214765. Unknown parameter |month= ignored (help)
  18. Sigurdsson A, Swedberg K (1994). "Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction". Eur. Heart J. 15 Suppl B: 14–9, discussion 26–30. PMID 8076657. Unknown parameter |month= ignored (help)
  19. The Acute Infarction Ramipril Efficacy—AIRE—Study Investigators : Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821-828.
  20. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670-1676.
  21. ISIS-4 Collaborative Group: ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-685.
  22. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico : GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343:1115-1122.
  23. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327:678-684.
  24. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, et al: Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994; 90:1731-1738.
  25. Pfeffer MA, Greaves SC, Arnold JM, Glynn RJ, LaMotte FS, Lee RT, Menapace Jr. FJ, Rapaport E, Ridker PM, Rouleau JL, Solomon SD, Hennekens CH: Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997; 95:2643-2651.
  26. Tokmakova M, Solomon SD: Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. Curr Opin Cardiol 2006; 21:268-272.
  27. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction: summary evidence from clinical trials. Circulation 1995;92:3132-7.
  28. Ambrosioni E, Borghi C, Magnani B, for the Survival Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
  29. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
  30. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998; 97:2202-12.
  31. Sigurdsson A, Swedberg K. Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction. Eur Heart 1994;15(Suppl B):14-9; discussion 26.
  32. 32.0 32.1 32.2 32.3 Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr; 2004 Writing Committee Members, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008 Jan 15;117(2):296-329 PMID 18071078

Template:SIB


Template:WikiDoc Sources